Pharmacokinetics, Safety, and Immunogenicity of a Biosimilar of Nivolumab (LY01015): A Randomized, Double-Blind, Parallel-Controlled Phase I Clinical Trial in Healthy Chinese Male Subjects
1. 当前求助状态已完结, 请及时下载应助文件
2. 系统将在 2025-07-15 10:20:31 删除文件
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1007/s40259-024-00679-w
文献链接: https://link.springer.com/10.1007/s40259-024-00679-w
其他信息:
出版社: Springer Science and Business Media LLC
作者: Wei Wang; Shengnan Zhang; Changlin Dou; Baihui Hu; Hongtao Song; Fan Qi; Yanyan Zhao; Xiaojing Li; Ming Zhou; Jinlian Xie; Kunhong Deng; Qian Wu; Ling Ye; Chang Cui; Li Liu; Jie Huang; Guoping Yang
全文下载地址: https://link.springer.com/content/pdf/10.1007/s40259-024-00679-w.pdf
